Document is current

Article History

Accepted: 4 May 2022

First Online: 8 July 2022

Compliance with Ethical Standards

:

: Muhammad Youshay Jawad, Yazen Alnefeesi, Felicia Ceban, Saja Jaberi, Leila Amirbeik, Lee Phan, Bing Cao, and Roger Ho each declare no potential conflicts of interest. Roger McIntyre has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Leanna M.W. Lui is a contractor Braxia Scientific Corp. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Kayla M. Teopiz has received personal fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp. David C.J. Chen-Li is a consultant to Braxia Scientific Corp.

: This article does not contain any studies with human or animal subjects performed by any of the authors.